In summary, while LDLR mutations produce more extreme lipid levels and clinical signs than APOB/PCSK9 mutations, all FD patients with severely elevated cholesterol are at risk for CVD, and the data show that no single gene group was statistically exempt from CVD. Here, PCSK9 is linked to Fabry disease.